Fingolimod: Completed Phase III enrollment

NVS completed enrollment in the double-blind, international Phase III TRANSFORMS trial comparing FTY720 vs. Avonex interferon beta-1a for 1 year. Avonex is marketed by Biogen Idec Inc. (BIIB, Cambr...